ABSOLUTE EASI TARGET IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF DATA FROM THE MEASURE UP 1 AND 2 STUDIES

被引：0
|
作者：
Prajapatil, Vimal [1 ,2 ,3 ,4 ,5 ,6 ]
Simpson, Eric L. [7 ]
Thyssen, Jacob P. [8 ]
Chovatiya, Raj [9 ]
Lane, Michael [10 ]
Teixeira, Henrique [10 ]
Calimlim, Brian [10 ]
Silverberg, Jonathan I. [11 ]
机构：
[1] Univ Calgary, Div Dermatol, Dept Med, Calgary, AB, Canada
[2] Univ Calgary, Sect Community Pediat, Dept Pediat, Calgary, AB, Canada
[3] Univ Calgary, Sect Pediat Rheumatol, Dept Pediat, Calgary, AB, Canada
[4] Skin Hlth & Wellness Ctr, Calgary, AB, Canada
[5] Dermatol Res Inst, Calgary, AB, Canada
[6] Prob Med Res, Calgary, AB, Canada
[7] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA
[8] Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark
[9] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA
[10] AbbVie Inc, N Chicago, IL USA
[11] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC 20052 USA
来源：
ACTA DERMATO-VENEREOLOGICA | 2022年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P4.17
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [41] Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib
    Kwatra, Shawn G.
    De Bruin-Weller, Marjolein
    Silverberg, Jonathan I.
    Lio, Peter
    Deleuran, Mette
    Aydin, Handan
    Calimlim, Brian M.
    Lane, Michael C.
    Liu, Yingyi
    Ofori, Sarah
    Weidinger, Stephan
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [42] Characterization of haematological and transaminase laboratory findings associated with upadacitinib use in moderate-to-severe atopic dermatitis: results of two phase III Trials (Measure Up 1 and 2)
    Silverberg, J. I.
    Gooderham, M. J.
    de Bruin-Weller, M. S.
    Papp, K. A.
    Aoki, V.
    Paller, A. S.
    Ofori, S.
    Tenorio, A. R.
    Liu, Y.
    Liu, J.
    Chovatiya, Raj
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E168 - E169
  • [43] Switching from dupilumab to abrocitinib in patients with moderate-to-severe atopic dermatitis: an analysis of responders and nonresponders to dupilumab
    Silverberg, Jonathan, I
    Simpson, Eric L.
    Thyssen, Jacob P.
    Pink, Andrew E.
    Weidinger, Stephan
    Chan, Gary
    Lazariciu, Irina
    Clibborn, Claire
    Guler, Erman
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [44] Dupilumab in moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials (SOLO 1 & 2)
    Simpson, E. L.
    Bieber, T.
    Guttman-Yassky, E.
    Beck, L. A.
    Blauvelt, A.
    Cork, M. J.
    Silverberg, J. I.
    Deleuran, M.
    Kataoka, Y.
    Lacour, J. -P.
    Kingo, K.
    Worm, M.
    Poulin, Y.
    Wollenberg, A.
    Soo, Y.
    Graham, N. M. H.
    Pirozzi, G.
    Akinlade, B.
    Staudinger, H.
    Mastey, V.
    Eckert, L.
    Gadkari, A.
    Ardeleanu, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 79 - 79
  • [45] ABSENTEEISM IN ADULT PATIENTS WITH MODERATE-TO-SEVERE TREATED ATOPIC DERMATITIS IN PORTUGAL: AN ECONOMETRIC ANALYSIS
    Pinheiro, B.
    Gouveia, M.
    Borges, M.
    VALUE IN HEALTH, 2019, 22 : S902 - S902
  • [46] Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis
    Ou, Zuzhen
    Chen, Chao
    Chen, Aijun
    Yang, Yao
    Zhou, Weikang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 54 : 303 - 310
  • [47] Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
    Wang, Fa-Ping
    Tang, Xiao-Ju
    Wei, Chuan-Qi
    Xu, Lin-Rui
    Mao, Hui
    Luo, Feng-Ming
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2018, 90 (02) : 190 - 198
  • [48] Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis
    Zimmermann, Marita
    Rind, David
    Chapman, Rick
    Kumar, Varun
    Kahn, Sonya
    Carlson, Josh
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (07) : 750 - 756
  • [49] Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
    Andrew Blauvelt
    Marjolein de Bruin-Weller
    Eric L. Simpson
    Zhen Chen
    Marius Ardeleanu
    Ana B. Rossi
    Dermatology and Therapy, 2022, 12 : 9 - 13
  • [50] Upadacitinib vs. dupilumab in adults with moderate-to-severe atopic dermatitis: analysis of the Heads Up phase III trial
    Blauvelt, A.
    Teixeira, H. D.
    Simpson, E. L.
    Costanzo, A.
    De Bruin-Weller, M.
    Barbarot, S.
    Prajapati, V. H.
    Lio, P.
    Hu, X.
    Wu, T.
    Liu, J.
    Ladizinski, B.
    Chu, A. D.
    Eyerich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E123 - E123
12345